This Article Full Text (PDF) All Versions of this Article: 1078155208097633v1 15/2/107    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Coutsouvelis, J. Articles by Corallo, C. E Search for Related Content PubMed PubMed Citation Articles by Coutsouvelis, J. Articles by Corallo, C. E Social Bookmarking                         What's this?

The management of prolonged, isolated hyperbilirubinemia following cytarabine-based chemotherapy for Acute Myeloid Leukaemia

Department of Pharmacy, Box Hill Hospital, Box Hill, Australia, John.coutsouvelis{at}easternhealth.org.au

Carmela E Corallo, B Pharm, Grad Dip Hosp Pharm

Department of Pharmacy, Box Hill Hospital, Box Hill, Australia

Background. Patients diagnosed with Acute Myeloid Leukaemia (AML) often receive cytarabine-based chemotherapy as standard treatment. Cytarabine is usually given in combination with other agents such as idarubicin. Such treatments are known to cause hepatic dysfunction characterized by a combination of jaundice, hyperbilirubinemia and increases in liver enzymes. Isolated hyperbilirubinemia is rarely reported. It is often difficult to identify a causative agent for the hepatic dysfunction, as there are often complicating factors such as sepsis.

Aim: To report a case of isolated hyperbilirubinemia in a patient treated with cytarabine-based chemotherapy for AML.

Clinical Details. After a diagnosis of AML the patient was admitted to hospital to receive induction chemotherapy consisting of high-dose cytarabine, idarubicin, and etoposide. All baseline laboratory results were normal, except the full blood evaluation that was consistent with AML. The chemotherapy was delivered over 7 days, and on the eighth day the patient had a bilirubin (BL) level of 27 umol/L

(normal range 522 umol/L). All other liver function tests (LFT) were normal. This isolated hyperbilirubinemia remained for the rest of the patient's admission, peaking on day 26, with a level of 255 umol/L. After a stay in the intensive care unit, the patient was discharged on day 45 with a bilirubin level of 33 umol/L. All other LFT remained unremarkable.

Outcome. The isolated hyperbilirubinemia resolved slowly and on day 68, when the patient was re-admitted for further dose-reduced cytarabine, the BL level was 21 umol/L. The patient was successfully retreated with this lower dose regimen.

Conclusion. Isolated hyperbilirubinemia is an uncommon presentation of cytarabine induced liver dysfunction. Resolution does occur but over a prolonged period. A lower dose of cytarabine for future treatment should be considered. J Oncol Pharm Practice (2009) 15: 107—110.

Key Words: acute myeloid leukemia (AML) • cytarabine • hyperbilirubinemia • chemotherapy • isolated hyperbilirubinemia

This version was published on June 1, 2009

Journal of Oncology Pharmacy Practice, Vol. 15, No. 2, 107-110 (2009)
DOI: 10.1177/1078155208097633


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?